Determine the necessary mass, volume, or concentration for preparing a solution.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Information
Niraparib (MK-4827) is a selective inhibitor ofPARP1/2withIC50of 3.8 nM/2.1 nM, with great activity in cancer cells with mutant BRCA-1 and BRCA-2. It is >330-fold selective against PARP3, V-PARP and Tank1. Niraparib can form PARP–DNA complexes resulting i
In vitro
In a whole cell assay, MK-4827 inhibited PARP activity with EC50 = 4 nM and inhibited proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10-100 nM range. It was demonstratedto be a potent and selective PARP-1 and PARP-2 inhibitor with IC50=3.8 and 2.1 nM, respectively. Furthermore, it displayed at least a 100-fold selectivity over PARP-3, V-PARP, and tankyrase-1, with IC50 = 1300, 330, and 570 nM, respectively. As well as inhibiting the growth of HeLa cell lacking BRCA-1 because of silencing by RNA interference, MK-4827 is able to inhibit the proliferation of cancer cell lines carrying natural BRCA-1 or BRCA-2 mutations. In MDA-MB-436 human mammary gland adenocarcinoma cells carrying BRCA-1 mutations, MK-4827 displayed CC50 = 18 nM, while in CAPAN-1 human pancreatic adenocarcinoma cells, which are BRCA-2 mutant, MK-4827 displayed CC50 = 90 nM. In contrast, normal human prostate and mammary epithelial cells are resistant to MK-4827, displaying antiproliferative effects in the micromolar range, thereby demonstrating the very high selective cytotoxicity from these PARP inhibitors in BRCA-1 and -2 mutant cancer cells compared to surrounding tissue.
In vivo
MK-4827, a novel, orally bioavailable, PARP-1 and PARP-2 inhibitor, strongly enhanced the effect of radiation on a variety of human tumor xenografts, both p53 wild type and p53 mutant. It was well tolerated in vivo and demonstrated efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer.
Cell Data
cell lines:Adrenocortical tumor cell line NCI-h295
Concentrations:serial dilutions
Incubation Time:7 days
Powder Purity:≥99%
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Löslichkeit | Solubility (25°C) In vitro DMSO: 40 mg/mL (98.22 mM); Ethanol: 3 mg/mL (7.36 mM); Water: Insoluble; |
|---|
H373:May causes damage to organs through prolonged or repeated exposure
H302:Harmful if swallowed
H340:May cause genetic defects
H361:Suspected of damaging fertility or the unborn child
P280:Wear protective gloves/protective clothing/eye protection/face protection.
P405:Store locked up.
P501:Dispose of contents/container to an approved waste disposal plant.
P264:Wash hands [and …] thoroughly after handling.
P260:Do not breathe dust/fume/gas/mist/vapors/spray.
P281:Use personal protective equipment as required.
P270:Do not eat, drink or smoke when using this product.
P330:Rinse mouth.
P203:Obtain, read and follow all safety instructions before use.
P301+P317:IF SWALLOWED: Get medical help.
P318:if exposed or concerned, get medical advice.
P319:Get medical help if you feel unwell.
No vendor-tested biological protocols are provided in the Product Data. The following protocols are general, literature-style examples suitable for research use; optimize for your system.
DMSO stock and dilution (general)
PARP biochemical inhibition assay (illustrative)
Cell-based target engagement (CETSA example)
LC–MS reference standard preparation
All procedures are for research use only. Follow institutional safety practices and SDS guidance.
Biochemical context for research use; no clinical claims are made.
Primary biochemical target (literature)
Mechanistic features (literature)
Cellular/biochemical consequences in research settings (literature)
Selectivity considerations (literature)
Experimental best practices
This compound is not a buffer reagent. However, it is frequently dosed into biochemical and cell-based assays prepared in buffered media. Practical guidance is provided for reliable use.
Preparing working solutions
Common assay buffers (examples; literature practice)
Handling notes
Not applicable aspects
As a discrete small-molecule probe, Niraparib itself is not substitutable by a “greener” reagent in the same sense as a solvent. However, greener choices can be made in the way it is handled, formulated, and analyzed.
Greener handling/solvent options (general)
Analytical method choices
Small comparison (qualitative)
Operational tips
These considerations target the process footprint around the compound rather than altering the compound itself.
This product is supplied strictly for research use and not for human or veterinary applications. No clinical or therapeutic claims are made.
Research/formulation context
Excipient status and pharmacopeia
Formulation notes for research
Compliance
Item-specific physicochemical specifications are not provided in the Product Data; consult the CoA/Spec Sheet for definitive values.
Item-specific values
Literature/general reference values (verify for your lot)
Practical handling notes (general)
This product is offered as Moligand™ grade within a small-molecule/compound library context, intended for research screening and discovery workflows.
What Moligand™ typically implies (general description)
Item-specific information (from Product Data)
Practical implications
Documentation
This product is primarily used as a research tool compound and reference standard rather than as a general reagent; nevertheless, it enables a range of discovery and analytical applications.
Research applications (from catalog context; expanded)
Derivatization/SAR (general chemistry)
Practical notes
All uses are for research purposes only; no clinical or diagnostic applications are implied.
This section provides general literature-style guidance relevant to modifying or using compounds of this class; it is not a specification for this item.
Stock solution preparation (common laboratory practice)
Representative transformations on related scaffolds (general)
Assay incubation conditions (biochemical, literature)
Analytical conditions (typical)
These are general conditions for comparable chemotypes and applications; adapt based on your system and confirm experimentally.
Safety information specific to this item is not fully specified in the Product Data. Always consult the SDS for authoritative guidance and institutional policies.
Item-specific guidance
GHS classification and hazard statements
General laboratory precautions (good practice for small-molecule research compounds)
Waste disposal
Special risks/notes
Niraparib is a heteroaromatic amide with a basic piperidine; solubility behavior is typical of neutral/weakly basic drug-like molecules.
Polarity and miscibility (literature, general)
Practical selection by application
Quick comparison (general)
Tips
Item-specific storage and shipping conditions are provided; additional best practices are included for robust performance in research workflows.
Item-specific conditions (from Product Data)
Reconstitution (general guidance)
Storage of solutions
Stability and specifications
Research use note
Concise identity and structural overview for professional users.
Item-specific identifiers (from Product Data)
Literature structural information (for reference only; verify against CoA)
2D structural description (general)
While primarily a finished probe compound, the Niraparib scaffold offers handles for chemical modification in medicinal chemistry and analytical derivatization.
Functional groups and reactivity (general)
Retrosynthetic motifs (literature, general)
Applications
Note: The above describes general synthetic logic for related scaffolds; it is not a lot-specific manufacturing route.
This section is adapted for a small-molecule probe (not an antibody). Information below reflects literature knowledge and should be validated in your system; no clinical claims are made.
Intended research target
Selectivity notes (literature)
Orthogonal verification
Not applicable (antibody-specific metadata)
Unser Leitfaden zur Qualitätsauswahl behandelt Reinheit, Stabilisatorstatus und Anwendungseignung für alle Varianten in unserem Katalog.
Moligand™ Qualitätsleitfaden ansehen →